B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report:

  • Disease epidemiology including – Patient segmentation, staging & progression rates, and Disease incidence/prevalence.
  • Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast
  • Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment
  • Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions.
  • Evaluation of indication-specific unmet needs, competitive assessment, and identifies key future players in the cell therapy market.
  • Pipeline products covering the following –
    • Early- to late-stage pipeline drugs
    • Breakdown by class of cell therapy
    • Ten-year sales projection
    • Likelihood of approval analysis
    • Breakdown by target

How is the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report different from other reports in the market?

  • Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031
  • Review updated prescription habits at the class level for already established therapies and compare their future projections to cell therapy pipeline drugs.
  • Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules
  • Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland, facilitating global R&D and investment strategies in countries that may be particularly promising for cell therapies
  • Compare region-and indication-specific market shares for prescribed drugs in NHL to identify market size and potential outside the 8 major markets

We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical companies
  • Biotech
  • CMOs, CMOs, CDMOs
  • Consulting Companies
  • Professional Services (e.g., Investment, Equity Companies, Banks)

To get a snapshot of the B-Cell Non-Hodgkins Lymphoma Drugs Market report, download a free report sample

B-Cell Non-Hodgkins Lymphoma Market Report Overview

The B-cell Non-Hodgkins Lymphoma market value for the 15 markets (15M) was $16.1 billion in 2021. NHL refers to a group of cancers that develop in the lymphatic system. NHL is characterized into three types: B-cell, T-cell, and NK lymphocyte lymphomas, of which B-Cell lymphomas are the most common, accounting for approximately 85% of all NHL.  NHL is diagnosed through a biopsy of the swollen lymph node. This is typically followed up with blood tests, a bone marrow aspiration, lumbar puncture, and full body imaging.

The B-Cell NHL market research report includes an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China)  for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical stage pipeline products, with a launch date assessment by market for B-cell non-Hodgkins lymphoma (NHL).

Market Size (2021 in 15M) $16.1 Billion
Key Regions North America, APAC, Europe, and The Middle East
Forecast Period 2021-2031
Future Players University College London Autolus Therapeutics Plc, University College London; NIHR Health Technology, Institute of Hematology and Blood Diseases Hospital; Juventas, Sian Wuhan Medical Technology Co Ltd, and Fred Hutchinson Cancer research Center, Celgene Corp

B-Cell NHL Market Drivers

Cell therapies are expected to capture around 35% of the B-cell NHL market by the end of the forecast period in 2031, reaching $8.4 billion in 8MM sales. In 2021, autologous CAR-T agents constituted 7% of the B-cell NHL market, with further growth expected over the forecast period. Autologous CAR-Ts will only face significant competition if allogeneic agents can demonstrate equivalent or superior efficacy. Allogeneic agents, which can be “off-the-shelf” products, are likely to have a lower price and a simpler manufacturing process.

Kymriah, Yescarta, Breyanzi, and Carteyva will receive label expansions into earlier lines of therapy and into new NHL subtypes. Ineligibility for intensive therapy and stem cell rescue, as well as an inadequate number of long-term remissions, creates a high level of unmet need. There will be a need for “off-the-shelf” products with lower costs and reduced infrastructure requirements.

B-Cell NHL Market Unmet Needs

NHL presents several unmet needs that may be addressed by cell therapies. The unmet need is largely in the R/R setting, where there are limited treatment options for many patients, particularly those who are not candidates for stem cell transplants. The four marketed CAR-Ts have already addressed some of these unmet needs, but some patients relapse after CAR-T therapy and require further treatment options. Autologous CAR-Ts are also prohibitively expensive and require personalized manufacture. Allogeneic pipeline therapies including CAR-Ts and CAR-NKs, which target differential antigens to marketed CAR-Ts, are well positioned to meet this unmet need if they demonstrate sufficient efficacy.

To know more about the unmet needs in the B-Cell NHL market, download a free sample report

B-Cell NHL Market Segmentation by Regions

The key regions in the B-Cell NHL market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.

B-Cell Non-Hodgkins Lymphoma Market Analysis by Regions, 2021 (%)

B-Cell NHL Market Analysis by Regions

For more regional insights on the B-Cell Non-Hodgkins Lymphoma market, download a free report sample

B-Cell NHL Market – Competitive Landscape

Some of the future players in the B-cell NHL market are University College London Autolus Therapeutics Plc, University College London; NIHR Health Technology, Institute of Hematology and Blood Diseases Hospital; Juventas, Sian Wuhan Medical Technology Co Ltd, and Fred Hutchinson Cancer research Center, Celgene Corp. Novartis is the leading sponsor of cell therapy trials in the B-cell NHL market, followed by Kite Pharma and Gilead.

For more insights on companies in the B-cell NHL market, download a free report sample

Segments Covered in the Report

B-Cell NHL Market Regions Outlook (Value, $Billion, 2021-2031)

  • North America
  • APAC
  • Europe
  • The Middle East

Reasons to Buy

The report will help to understand:

  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication?
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in each market?
  • What is the total market value projected for the forecast end, in 2031?

Bristol-Myers Squibb
JW Therapeutics
Merck & Co
Allogene Therapeutics
Caribou Biosciences
Fate Therapeutics

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology & Epidemiology

3.2. B-Cell NHL Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell Therapies Forecast Methodology Overview

10.2. Pricing of Cell Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031 in real time.

  • Access a live B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.